Takeda To Press On With Core R&D Strategy Post-Shire

Just over two years into its five-year effort to fundamentally transform its R&D activities, Takeda Pharmaceutical Co. Ltd. says the initiative has led to a more focused approach and an enlarged pipeline, fueled by an open approach to partnering.

With a global emphasis on oncology, gastroenterology, neuroscience and vaccines, the company's drug discovery units have been halved over the past few years to three